Anti-KIR3DL2 therapy in the treatment of Sézary syndrome

Affiliations

Comment

Pietro Quaglino. Lancet Oncol. 2019 Aug.

. 2019 Aug;20(8):1048-1049.

doi: 10.1016/S1470-2045(19)30393-6. Epub 2019 Jun 25.

¹ Dermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Turn 10126, Italy. Electronic address: pietro.quaglino@unito.it.

No abstract available

Comment on

IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.
Bagot M, Porcu P, Marie-Cardine A, Battistella M, William BM, Vermeer M, Whittaker S, Rotolo F, Ram-Wolff C, Khodadoust MS, Bensussan A, Paturel C, Bonnafous C, Sicard H, Azim HA Jr, Kim YH. Bagot M, et al. Lancet Oncol. 2019 Aug;20(8):1160-1170. doi: 10.1016/S1470-2045(19)30320-1. Epub 2019 Jun 25. Lancet Oncol. 2019. PMID: 31253572 Clinical Trial.